Taken together, these findings suggested that treatment with metformin coupled with vorinostat significantly improved EGFR-TKI sensitivity in NSCLC cells that exhibit intrinsic or aquired EGFR-TKI resistance, and did so by inducing BIM-dependent apoptosis. Here, EGFR is linked to non-small cell lung carcinoma.